
Scribe Therapeutics and Sanofi collaborate on in vivo therapies for sickle cell disease
BioWorld
|
July 18, 2023
X min read
BioWorld
|
July 18, 2023
Share on Social
More like this
News
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now
Press
Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference
March 7, 2025
Read Now